BioMark Diagnostics Inc
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for wo… Read more
BioMark Diagnostics Inc (BMKDF) - Total Liabilities
Latest total liabilities as of December 2024: $1.97 Million USD
Based on the latest financial reports, BioMark Diagnostics Inc (BMKDF) has total liabilities worth $1.97 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BioMark Diagnostics Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how BioMark Diagnostics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BioMark Diagnostics Inc Competitors by Total Liabilities
The table below lists competitors of BioMark Diagnostics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Willowglen MSC Bhd
KLSE:0008
|
Malaysia | RM51.65 Million |
|
Gia Lai Electricity JSC
VN:GEG
|
Vietnam | ₫8.69 Trillion |
|
Gauzy Ltd. Ordinary Shares
NASDAQ:GAUZ
|
USA | $118.95 Million |
|
Taiwan Thick-Film Ind
TWO:6246
|
Taiwan | NT$828.96 Million |
|
Havila Shipping ASA
OL:HAVI
|
Norway | Nkr1.17 Billion |
|
Promimic AB
ST:PRO
|
Sweden | Skr16.60 Million |
|
Shengfeng Development Limited Class A Ordinary Shares
NASDAQ:SFWL
|
USA | $166.27 Million |
|
Garuda Maintenance Facility AeroAsia Tbk PT
JK:GMFI
|
Indonesia | Rp658.98 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down BioMark Diagnostics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioMark Diagnostics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioMark Diagnostics Inc (2014–2024)
The table below shows the annual total liabilities of BioMark Diagnostics Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-03-31 | $1.70 Million | -9.74% |
| 2023-03-31 | $1.88 Million | -10.70% |
| 2022-03-31 | $2.11 Million | +104.19% |
| 2021-03-31 | $1.03 Million | -4.12% |
| 2020-03-31 | $1.08 Million | -14.16% |
| 2019-03-31 | $1.25 Million | +31.69% |
| 2018-03-31 | $952.17K | -13.80% |
| 2017-03-31 | $1.10 Million | +87.84% |
| 2016-03-31 | $588.05K | +613.87% |
| 2015-03-31 | $82.37K | +1520.58% |
| 2014-03-31 | $5.08K | -- |